MedMira Inc. (MIR.V)
CAD 0.08
(-5.88%)
CAD 0.08
(-5.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.57 Million CAD | -47.79% |
| 2022 | -1.06 Million CAD | -675.95% |
| 2021 | 185.29 Thousand CAD | 116.45% |
| 2020 | -1.12 Million CAD | 11.79% |
| 2019 | -1.27 Million CAD | 26.83% |
| 2018 | -1.74 Million CAD | 17.37% |
| 2017 | -2.11 Million CAD | 48.72% |
| 2016 | -4.11 Million CAD | -73.26% |
| 2015 | -2.63 Million CAD | 23.03% |
| 2014 | -2.98 Million CAD | -28.12% |
| 2013 | -2.41 Million CAD | -12.6% |
| 2012 | 7.18 Million CAD | -65.28% |
| 2011 | -1.29 Million CAD | 43.77% |
| 2010 | -1.98 Million CAD | 7.28% |
| 2009 | -2.48 Million CAD | 22.96% |
| 2008 | -3.14 Million CAD | 3.81% |
| 2007 | -3.35 Million CAD | 36.37% |
| 2006 | -5.26 Million CAD | -21.55% |
| 2005 | -4.33 Million CAD | -37.15% |
| 2004 | -3.16 Million CAD | 20.29% |
| 2003 | -3.96 Million CAD | 17.2% |
| 2002 | -4.78 Million CAD | 24.37% |
| 2001 | -6.33 Million CAD | -112.11% |
| 2000 | -2.98 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -479.82 Thousand CAD | 42.48% |
| 2024 Q1 | -541.77 Thousand CAD | -38.55% |
| 2024 Q3 | -601.61 Thousand CAD | -75.81% |
| 2023 FY | - CAD | -47.79% |
| 2023 Q3 | -413 Thousand CAD | -30.49% |
| 2023 Q4 | -403.01 Thousand CAD | 2.42% |
| 2023 Q2 | -316.51 Thousand CAD | 28.83% |
| 2023 Q1 | -444.71 Thousand CAD | -80.39% |
| 2022 Q2 | -306.55 Thousand CAD | -12.94% |
| 2022 Q1 | -271.43 Thousand CAD | 34.94% |
| 2022 FY | - CAD | -675.95% |
| 2022 Q4 | -246.53 Thousand CAD | -1.57% |
| 2022 Q3 | -242.71 Thousand CAD | 20.82% |
| 2021 Q3 | -136.3 Thousand CAD | 34.07% |
| 2021 Q1 | 945.59 Thousand CAD | 4670.72% |
| 2021 Q2 | -206.76 Thousand CAD | -121.87% |
| 2021 Q4 | -417.21 Thousand CAD | -206.08% |
| 2021 FY | - CAD | 116.45% |
| 2020 Q2 | -384.84 Thousand CAD | -63.01% |
| 2020 Q4 | -20.68 Thousand CAD | 95.73% |
| 2020 Q1 | -236.08 Thousand CAD | 23.02% |
| 2020 Q3 | -484.97 Thousand CAD | -26.02% |
| 2020 FY | - CAD | 11.79% |
| 2019 Q1 | -296.56 Thousand CAD | -3.5% |
| 2019 FY | - CAD | 26.83% |
| 2019 Q2 | -367.92 Thousand CAD | -24.06% |
| 2019 Q3 | -305 Thousand CAD | 17.1% |
| 2019 Q4 | -306.68 Thousand CAD | -0.55% |
| 2018 FY | - CAD | 17.37% |
| 2018 Q1 | -513.22 Thousand CAD | -20.68% |
| 2018 Q3 | -498.53 Thousand CAD | 4.4% |
| 2018 Q2 | -521.47 Thousand CAD | -1.61% |
| 2018 Q4 | -286.53 Thousand CAD | 42.53% |
| 2017 Q4 | -425.29 Thousand CAD | 29.15% |
| 2017 Q2 | -402.36 Thousand CAD | 41.21% |
| 2017 FY | - CAD | 48.72% |
| 2017 Q1 | -684.44 Thousand CAD | 57.94% |
| 2017 Q3 | -600.28 Thousand CAD | -49.19% |
| 2016 Q1 | -685.63 Thousand CAD | -817.51% |
| 2016 Q4 | -1.62 Million CAD | -60.23% |
| 2016 Q3 | -1.01 Million CAD | -28.5% |
| 2016 FY | - CAD | -73.26% |
| 2016 Q2 | -790.39 Thousand CAD | -15.28% |
| 2015 Q1 | -722.33 Thousand CAD | -119.36% |
| 2015 FY | - CAD | 23.03% |
| 2015 Q4 | -74.72 Thousand CAD | 88.52% |
| 2015 Q3 | -650.74 Thousand CAD | 29.15% |
| 2015 Q2 | -918.49 Thousand CAD | -27.16% |
| 2014 Q1 | -586.95 Thousand CAD | -662.02% |
| 2014 FY | - CAD | -28.12% |
| 2014 Q2 | -1.15 Million CAD | -96.94% |
| 2014 Q3 | -1 Million CAD | 13.28% |
| 2014 Q4 | -329.29 Thousand CAD | 67.15% |
| 2013 Q3 | -761.04 Thousand CAD | -43.25% |
| 2013 Q1 | -469.29 Thousand CAD | 21.35% |
| 2013 FY | - CAD | -12.6% |
| 2013 Q2 | -531.27 Thousand CAD | -13.21% |
| 2013 Q4 | 104.43 Thousand CAD | 113.72% |
| 2012 Q4 | -596.66 Thousand CAD | -9.86% |
| 2012 Q3 | -543.12 Thousand CAD | 48.54% |
| 2012 FY | - CAD | -65.28% |
| 2012 Q1 | -164.62 Thousand CAD | -219.3% |
| 2012 Q2 | -1.05 Million CAD | -541.07% |
| 2011 Q1 | -440.75 Thousand CAD | 56.93% |
| 2011 Q2 | -614.44 Thousand CAD | -39.41% |
| 2011 Q3 | -377.89 Thousand CAD | 38.5% |
| 2011 FY | - CAD | 43.77% |
| 2011 Q4 | 137.99 Thousand CAD | 136.52% |
| 2010 Q1 | -517.57 Thousand CAD | 36.37% |
| 2010 FY | - CAD | 7.28% |
| 2010 Q2 | -519.74 Thousand CAD | -0.42% |
| 2010 Q3 | -241.53 Thousand CAD | 53.53% |
| 2010 Q4 | -1.02 Million CAD | -323.65% |
| 2009 Q4 | -813.36 Thousand CAD | -75.49% |
| 2009 Q2 | -674.38 Thousand CAD | -26.45% |
| 2009 Q1 | -533.33 Thousand CAD | 57.69% |
| 2009 FY | - CAD | 22.96% |
| 2009 Q3 | -463.48 Thousand CAD | 31.27% |
| 2008 FY | - CAD | 3.81% |
| 2008 Q3 | -611.63 Thousand CAD | -23.49% |
| 2008 Q2 | -495.3 Thousand CAD | 28.34% |
| 2008 Q1 | -691.2 Thousand CAD | 24.3% |
| 2008 Q4 | -1.26 Million CAD | -106.11% |
| 2007 Q4 | -913.03 Thousand CAD | -73.77% |
| 2007 Q3 | -525.41 Thousand CAD | 43.11% |
| 2007 Q2 | -923.58 Thousand CAD | 6.54% |
| 2007 Q1 | -988.25 Thousand CAD | 40.09% |
| 2007 FY | - CAD | 36.37% |
| 2006 Q2 | -685.03 Thousand CAD | 45.56% |
| 2006 Q1 | -1.25 Million CAD | 12.58% |
| 2006 Q3 | -1.67 Million CAD | -144.69% |
| 2006 Q4 | -1.64 Million CAD | 1.59% |
| 2006 FY | - CAD | -21.55% |
| 2005 Q4 | -1.43 Million CAD | -39.2% |
| 2005 Q3 | -1.03 Million CAD | -0.87% |
| 2005 Q2 | -1.02 Million CAD | -22.58% |
| 2005 Q1 | -836.35 Thousand CAD | -37.63% |
| 2005 FY | - CAD | -37.15% |
| 2004 Q2 | -869.57 Thousand CAD | -11.64% |
| 2004 Q3 | -904.47 Thousand CAD | -4.01% |
| 2004 Q1 | -778.89 Thousand CAD | -20.43% |
| 2004 FY | - CAD | 20.29% |
| 2004 Q4 | -607.67 Thousand CAD | 32.81% |
| 2003 Q1 | -866 Thousand CAD | 55.16% |
| 2003 FY | - CAD | 17.2% |
| 2003 Q2 | -958.34 Thousand CAD | -10.66% |
| 2003 Q3 | -1.49 Million CAD | -55.81% |
| 2003 Q4 | -646.75 Thousand CAD | 56.69% |
| 2002 Q3 | -947.47 Thousand CAD | -21.73% |
| 2002 Q1 | -1.13 Million CAD | 0.0% |
| 2002 Q4 | -1.93 Million CAD | -103.83% |
| 2002 FY | - CAD | 24.37% |
| 2002 Q2 | -778.34 Thousand CAD | 31.22% |
| 2001 FY | - CAD | -112.11% |
| 2000 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arch Biopartners Inc. | -430.71 Thousand CAD | -266.188% |
| Covalon Technologies Ltd. | -3.49 Million CAD | 54.828% |
| Hemostemix Inc. | -1.94 Million CAD | 18.94% |
| Universal Ibogaine Inc. | -4.6 Million CAD | 65.767% |
| Kane Biotech Inc. | -3.23 Million CAD | 51.236% |
| Marvel Biosciences Corp. | -2.25 Million CAD | 29.963% |
| NervGen Pharma Corp. | -17.72 Million CAD | 91.1% |
| XORTX Therapeutics Inc. | -6.46 Million CAD | 75.617% |